Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, Inc. (CLDX), bought 1,050 shares at $4.83 ($5K) on 2020-06-10, disclosed to the SEC on 2020-06-11.
Open-market purchase of $5k CLDX by SVP of Corporate Affairs & Administration. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| Filing → |
| CLDX | SELL | 2021-12-10 | $293K | — | Filing → |
| CLDX | SELL | 2021-11-03 | $595K | — | Filing → |